CompletedNot Applicable

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

United States98 participantsStarted 2005-04

Plain-language summary

RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.

Who can participate

Age range120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed cancer, including, but not limited to, the following: * Melanoma * Breast cancer * Invasive squamous cell cancer * Other cancers for which patients underwent or will undergo the following: * Adequate archived paraffin-embedded tissue for making slides for immunostaining * Adequate freshly removed sentinel lymph node (and primary tumor, if available) tissue for laboratory assays * Clinical data and date of last follow-up on tumor stage and status must be available * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

What they're measuring

OX-40 expression

Timeframe: During immunostaining

Disease-free survival

Timeframe: During data analysis

Trial details

NCT IDNCT00900302

SponsorOHSU Knight Cancer Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-03

View on ClinicalTrials.gov More Cancer trials